汪迪飛 綜述,翟 瑄審校
(重慶醫(yī)科大學(xué)附屬兒童醫(yī)院神經(jīng)外科 400014)
?
兒童腦積水外科治療進(jìn)展*
汪迪飛 綜述,翟瑄△審校
(重慶醫(yī)科大學(xué)附屬兒童醫(yī)院神經(jīng)外科400014)
腦積水;神經(jīng)內(nèi)窺鏡檢查;第三腦室;腦室-腹腔分流術(shù);神經(jīng)內(nèi)鏡第三腦室底造瘺術(shù);兒童
腦積水是小兒神經(jīng)外科常見(jiàn)疾病之一,在臨床表現(xiàn)上有其自身特點(diǎn)。兒童腦積水的治療主要依靠外科手術(shù),臨床應(yīng)用最多的是腦室-腹腔分流術(shù)和神經(jīng)內(nèi)鏡第三腦室底造瘺術(shù)。腦室-腹腔分流術(shù)是最常用的術(shù)式,但術(shù)后并發(fā)癥較多。神經(jīng)內(nèi)鏡第三腦室底造瘺術(shù)對(duì)非交通性腦積水有良好療效,也是分流術(shù)失敗患兒的另一選擇。本文就兒童腦積水手術(shù)治療方法及其并發(fā)癥處理的最新研究進(jìn)展作一綜述。
兒童腦積水的病因以先天性為主,約占先天性神經(jīng)系統(tǒng)發(fā)育畸形的1/3。也可繼發(fā)于腦室內(nèi)出血、腦腫瘤、Dandy-Walker畸形、Chiari畸形、中樞系統(tǒng)感染、腦外傷等疾病。有資料顯示,兒童腦積水發(fā)病率約為1/1 000[1]。臨床表現(xiàn)上,由于患兒顱骨骨縫及前囟未閉合而導(dǎo)致高顱壓癥狀不明顯,2歲以內(nèi)的患兒以頭圍異常增大、前囟飽滿、頭皮靜脈怒張等體征為主要表現(xiàn)[2]。
2.1腦室-腹腔分流術(shù)歷史上,腦積水的治療始于對(duì)腦脊液整體流動(dòng)模型深入的探索。20世紀(jì)早期已開始嘗試人為設(shè)置旁路,以繞開腦脊液通路阻塞的部位,方法為開放性的顱骨切開術(shù)或是通過(guò)簡(jiǎn)陋神經(jīng)內(nèi)鏡減少腦脊液的產(chǎn)生,取得了一些成效,但病死率很高[3]。隨著硅膠管和早期活瓣裝置的出現(xiàn),治療的方法開始趨向用腦脊液分流的機(jī)械瓣膜導(dǎo)管。如今,腦脊液分流術(shù)已成為了腦積水的標(biāo)準(zhǔn)治療方法,適用于各種類型腦積水的臨床治療。最常見(jiàn)的腦脊液分流轉(zhuǎn)移類型是從腦室至腹腔,即腦室-腹腔分流術(shù)(ventriculo-peritoneal shunt,VPS);亦有向其他遠(yuǎn)端部位的分流選擇,如引流至右心房和胸腔。分流術(shù)一般要使用自頭部至腹部皮下走行的帶有活瓣的硅膠導(dǎo)管,壓力差或流量-調(diào)節(jié)活瓣裝置經(jīng)常與抗虹吸或重力裝置聯(lián)合使用,用于防止姿勢(shì)相關(guān)性虹吸作用引起的腦脊液引流過(guò)度。自1952年Nulsen和Spitz報(bào)道了應(yīng)用彈簧和不銹鋼球閥制造的分流裝置進(jìn)行腦室頸靜脈分流術(shù)后,腦積水的治療發(fā)生了革命性的變化。其中可調(diào)壓分流管的應(yīng)用是腦積水治療上一個(gè)提高,尤其是對(duì)于兒童單純性腦積水的治療效果提升明顯。可調(diào)壓式分流管有自身的優(yōu)勢(shì),其壓力選擇范圍較大且能夠設(shè)置合適患者的個(gè)體化分流壓力,還可以在術(shù)后根據(jù)分流效果及時(shí)調(diào)節(jié)。近幾年出現(xiàn)的Certas分流管,內(nèi)置一個(gè)可調(diào)式球-彈簧裝置,能通過(guò)外部的磁力引導(dǎo)來(lái)調(diào)整體內(nèi)導(dǎo)管活瓣的開口大小,目前已在實(shí)驗(yàn)室中實(shí)現(xiàn)了對(duì)不同分流壓力的調(diào)整,實(shí)際的療效仍有待臨床工作的檢驗(yàn)[4]。近年來(lái)已有學(xué)者報(bào)道可調(diào)壓分流管在兒童腦積水的治療上取得了良好效果[5]。
2.2神經(jīng)內(nèi)鏡第三腦室底造瘺術(shù)20世紀(jì)90年代,神經(jīng)內(nèi)鏡下第三腦室底造瘺術(shù)(endoscopic third ventriculostomy,ETV)作為一個(gè)有效的備選治療方法開始得到應(yīng)用,目前已在高收入國(guó)家的小兒神經(jīng)外科中心成為常規(guī)開展的主要手術(shù)[1]。術(shù)中將神經(jīng)內(nèi)鏡放入側(cè)腦室前角,通過(guò)室間孔進(jìn)入第三腦室,在第三腦底造一瘺口,與腦橋前池交通。ETV主要適用于因腦脊液循環(huán)通路梗阻而無(wú)吸收障礙的非交通性腦積水,尤其對(duì)各種原因?qū)е碌膶?dǎo)水管梗阻引起的腦積水有較好的效果。對(duì)于分流手術(shù)失敗患者的治療,神經(jīng)內(nèi)鏡也取得了良好的效果。國(guó)外Sufianov等[6]報(bào)道了28例分流術(shù)失敗患者行ETV成功率達(dá) 80%,這無(wú)疑成為分流術(shù)失敗患者的另一個(gè)治療選擇。與分流術(shù)相比,神經(jīng)內(nèi)鏡手術(shù)治療有自身的優(yōu)點(diǎn),其基本接近腦脊液循環(huán)的生理狀態(tài),沒(méi)有分流裝置植入帶來(lái)的并發(fā)癥。對(duì)于擬行ETV的患兒的入選標(biāo)準(zhǔn)應(yīng)包括:有高顱壓臨床表現(xiàn)影像學(xué)資料證實(shí),第四腦室正中孔至中腦導(dǎo)水管水平各種原因所致的狹窄或閉塞引起的梗阻性腦積水三腦室擴(kuò)大超過(guò)內(nèi)鏡的直徑且三腦室底平坦以便保證足夠內(nèi)鏡操作空間,患者的腦脊液吸收和回流應(yīng)該是正常的。ETV主要適用于非交通性腦積水,由于其成功有兩個(gè)前提:患者的腦脊液吸收能力正常;蛛網(wǎng)膜下腔腦脊液循環(huán)通暢,所以選擇不同病因的腦積水患兒會(huì)對(duì)手術(shù)結(jié)果產(chǎn)生直接的影響。盡管ETV在很多患者身上取得了成功,但目前仍存在較高的早期失敗率,特別是對(duì)于年齡較小的患兒[7]。從2000年開始,脈絡(luò)叢燒灼術(shù)(choroid plexus cauterisation,CPC)被加入到ETV術(shù)中用于提高對(duì)幼兒的療效[8],目前已在一些試驗(yàn)地區(qū)實(shí)行CPC與ETV聯(lián)合使用[8]。CPC與ETV手術(shù)需要使用一個(gè)柔韌的神經(jīng)內(nèi)鏡來(lái)燒灼貫穿兩個(gè)側(cè)腦室壁的全部脈絡(luò)叢。有研究表明[9-12],與單獨(dú)應(yīng)用ETV相比,ETV與CPC聯(lián)合應(yīng)用對(duì)1歲以內(nèi)的患兒有更好的療效[8]。此外,ETV與CPC聯(lián)合應(yīng)用的療效與燒灼脈絡(luò)叢的總量呈正比[13]。初步研究結(jié)果表明,與單用ETV或VPS相比,ETV與CPC聯(lián)合應(yīng)用似乎對(duì)兒童的認(rèn)知功能沒(méi)有負(fù)面影響[14]?;谠谠囼?yàn)地區(qū)取得的良好結(jié)果,ETV與CPC已被引入美國(guó)和加拿大,并且在一系列臨床研究中取得了令人滿意的效果[15]。
3.1腦室分流術(shù)并發(fā)癥及其處理經(jīng)過(guò)治療的腦積水患兒面臨許多潛在的長(zhǎng)期并發(fā)癥,通常與治療有關(guān)。分流手術(shù)的圍術(shù)期病死率約為0.5%[16],術(shù)后30年病死率約為5.0%~10.0%[17]。分流術(shù)失敗最常見(jiàn)的原因是機(jī)械性梗阻,多發(fā)生于初次置管兩年后,約40%的患兒需要再次手術(shù)治療,并且存在術(shù)后再次梗阻的風(fēng)險(xiǎn)[18]。分流管出現(xiàn)阻塞后需要緊急手術(shù),以確認(rèn)并替換分流導(dǎo)管阻塞的部分。癥狀不明顯時(shí)(如慢性頭痛或?qū)W習(xí)成績(jī)下降),對(duì)顱內(nèi)壓的監(jiān)測(cè)可幫助提示分流梗阻的存在。有統(tǒng)計(jì)資料顯示,分流術(shù)后感染發(fā)生率約為5.0%~9.0%[19-20],最容易發(fā)生于術(shù)后3個(gè)月內(nèi)[21],臨床表現(xiàn)為發(fā)熱、煩躁、傷口紅斑或是分流障礙的癥狀,從分流器孔獲得的腦脊液病原體檢查結(jié)果陽(yáng)性可確診感染。常見(jiàn)的病原體是表皮共生物,包括凝固酶陰性葡萄球菌、金黃色葡萄球菌,以及不常見(jiàn)的丙酸桿菌[19,22-23]。罕見(jiàn)的分流感染由腹腔內(nèi)的腦脊液假性囊腫引起,表現(xiàn)出腹部癥狀[24]。有研究顯示,預(yù)防性使用全身性抗生素及進(jìn)行標(biāo)準(zhǔn)化手術(shù)治療方案似乎能減少感染的風(fēng)險(xiǎn)[20,25]。另一項(xiàng)研究顯示,使用克林霉素和利福平浸泡分流導(dǎo)管可能會(huì)降低感染的概率[19,26-27],但從正在進(jìn)行的BASICS試驗(yàn)(比較抗生素浸潤(rùn)導(dǎo)管,浸銀導(dǎo)管和標(biāo)準(zhǔn)導(dǎo)管)獲得的隨機(jī)數(shù)據(jù)仍有待處理[28]。腦脊液過(guò)度引流會(huì)引起急性硬膜下積液或血腫,或是慢性裂隙腦綜合征[29]。對(duì)這些并發(fā)癥的治療選擇仍然存在爭(zhēng)議,目前的手術(shù)方法包括調(diào)整分流裝置減少腦脊液過(guò)度引流,引流到腰椎蛛網(wǎng)膜下隙,以及顱穹窿擴(kuò)張術(shù)等[29]。
3.2ETV并發(fā)癥及其處理有統(tǒng)計(jì)資料顯示,ETV術(shù)后兩年失敗的發(fā)生率約為35%[30],但對(duì)年齡及發(fā)病原因等獨(dú)立的預(yù)后因素應(yīng)給予特別的重視[7]。在經(jīng)過(guò)驗(yàn)證的ETV成功分?jǐn)?shù)中已將這些獨(dú)立的預(yù)后因素量化了[7,31],它能精確地將患者分為ETV成功率高(≥80%),成功率中等(50%~70%),成功率低(≤40%)3個(gè)群組[32]。絕大多數(shù)ETV失敗發(fā)生在術(shù)后6個(gè)月內(nèi)[7,33-34]。相對(duì)于分流手術(shù),EVT的并發(fā)癥較少且大部分是短暫性的,主要有顱內(nèi)積氣,顱內(nèi)感染,硬膜下積液,術(shù)后發(fā)熱,一過(guò)性的動(dòng)眼神經(jīng)麻痹,下丘腦損傷等,與血管損傷有關(guān)的并發(fā)癥較少發(fā)生,包括腦室內(nèi)或腦內(nèi)出血、蛛網(wǎng)膜下腔出血和繼發(fā)于血管損傷的腦梗死等[35-36]。對(duì)于積氣、積液、發(fā)熱等并發(fā)癥只需術(shù)后對(duì)癥處理,一般都能自行治愈。其他嚴(yán)重并發(fā)癥很少見(jiàn),包括基底動(dòng)脈損傷(0.2%),永久性內(nèi)分泌失調(diào)(0.9%),下丘腦或其他腦組織的損傷(0.2%),以及手術(shù)期的死亡(0.2%)[37]。
兒童腦積水作為小兒神經(jīng)外科常見(jiàn)疾病,目前的治療方法仍主要依靠手術(shù)??烧{(diào)式分流管的應(yīng)用,使分流術(shù)的治療效果有了很大的提高,已成為目前兒童腦積水治療的首選。ETV創(chuàng)傷小,治療后可使患兒腦脊液循環(huán)接近正常生理狀態(tài),更符合目前臨床外科的治療理念。兩種手術(shù)如今已得到廣泛開展,在臨床上取得了良好的治療效果,但依然存在許多不足,在手術(shù)成功率的提高及對(duì)術(shù)后并發(fā)癥的預(yù)防和處理等多方面問(wèn)題仍需要進(jìn)一步的探索和解決。
[1]Tully HM,Dobyns WB.Infantile hydrocephalus:a review of epidemiology,classification and causes[J].Eur J Med Genet,2014,57(8):359-368.
[2]Kahle KT,Kulkarni AV,Limbrick DD,et al.Hydrocephalus in children[J].Lancet,2015(15):60694-60698.
[3]Warf BC.Three steps forward and 2 steps back:the Echternach procession toward optimal hydrocephalus treatment[J].Neurosurgery,2014,61(Suppl 1):105-110.
[4]Czosnyka Z,Pickard JD,Czosnyka M,et al.Hydrodynamic properties of the Certas hydrocephalus shunt laboratory investigation[J].Neurosurg Pediatr,2013,11(2):198-204.
[5]Weinzierl MR,Rohde V,Gilsbach JM,et al.Management of hydrocephalus in infants by using shunts with adjustable valves[J].J Neurosurg Pediatr,2008,2(1):14-18.
[6]Sufianov A,Sufianova G,Iakimov I.Neuroendoscopic procedures in achievement of shunt independence:outcome analysis of 28 patients with shunt malfunction[J].Minim Invasive Neurosurg,2008,51(3):158-164.
[7]Kulkarni AV,Drake JM,Mallucci CL,et al.Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus[J].J Pediatr,2009,155(2):254-259.
[8]Warf BC.Comparison of endoscopic third ventriculostomy alone and combined with choroid plexus cauterization in infants younger than 1 year of age:a prospective study in 550 African children[J].J Neurosurg,2005,103(6 Suppl):475-481.
[9]Warf BC.Congenital idiopathic hydrocephalus of infancy:the results of treatment by endoscopic third ventriculostomy with or without choroid plexus cauterization and suggestions for how it works[J].Childs Nerv Syst,2013,29(6):935-940.
[10]Warf BC,Tracy S,Mugamba J.Long-term outcome for endoscopic third ventriculostomy alone or in combination with choroid plexus cauterization for congenital aqueductal stenosis in African infants[J].J Neurosurg Pediatr,2012,10(2):108-111.
[11]Warf BC,Dewan M,Mugamba J.Management of Dandy-Walker complex-associated infant hydrocephalus by combined endoscopic third ventriculostomy and choroid plexus cauterization[J].J Neurosurg Pediatr,2011,8(4):377-383.
[12]Warf BC.Hydrocephalus associated with neural tube defects:characteristics,management,and outcome in sub-Saharan Africa[J].Childs Nerv Syst,2011,27(10):1589-1594.
[13]Warf BC,Mugamba J,Kulkarni AV.Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus in Uganda:report of a scoring system that predicts success[J].J Neurosurg Pediatr,2010,5(2):143-148.
[14]Warf B,Ondoma S,Kulkarni A,et al.Neurocognitive outcome and ventricular volume in children with myelomeningocele treated for hydrocephalus in Uganda[J].J Neurosurg Pediatr,2009,4(6):564-570.
[15]Kulkarni AV,Riva-Cambrin J,Browd SR,et al.Endoscopic third ventriculostomy and choroid plexus cauterization in infants with hydrocephalus:a retrospective Hydrocephalus Clinical Research Network study[J].Neurosurg Pediatr,2014,14(3):224-229.
[16]Smith ER,Butler WE,Barker FG.In-hospital mortality rates after ventriculoperitoneal shunt procedures in the United States,1998 to 2000:relation to hospital and surgeon volume of care[J].J Neurosurg,2004,100(2 Suppl Pediatrics):90-97.
[17]Vinchon M,Baroncini M,Delestret I.Adult outcome of pediatric hydrocephalus[J].Childs Nerv Syst,2012,28(6):847-854.
[18]Kulkarni AV,Riva-Cambrin J,Butler J.Outcomes of CSF shunting in children:comparison of Hydrocephalus Clinical Research Network cohort with historical controls:clinical article[J].Neurosurg Pediatr,2013,12(4):334-338.
[19]Kandasamy J,Dwan K,Hartley JC,et al.Antibiotic-impregnated ventriculoperitoneal shunts——a multi-centre British paediatric neurosurgery group (BPNG) study using historical controls[J].Childs Nerv Syst,2011,27(4):575-581.
[20]Kestle JR,Riva-Cambrin J,Wellons JC,et al.A standardized protocol to reduce cerebrospinal fluid shunt infection:the Hydrocephalus Clinical Research Network Quality Improvement Initiative[J].Neurosurg Pediatr,2011,8(1):22-29.
[21]Kulkarni AV,Drake JM,Lamberti-Pasculli M.Cerebrospinal fluid shunt infection:a prospective study of risk factors[J].J Neurosurg,2001,94(2):195-201.
[22]Simon TD,Butler J,Whitlock KB,et al.Risk factors for first cerebrospinal fluid shunt infection:findings from a multi-center prospective cohort study[J].J Pediatr,2014,164(6):1462-1468.
[23]Tuan TJ,Thorell EA,Hamblett NM,et al.Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children[J].Pediatr Infect Dis J,2011,30(9):731-735.
[24]Kariyattil R,Steinbok P,Singhal A,et al.Ascites and abdominal pseudocysts following ventriculoperitoneal shunt surgery:variations of the same theme[J].J Neurosurg,2007,106(5 Suppl):350-353.
[25]Ratilal B,Costa J,Sampaio C.Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts:a systematic review[J].J Neurosurg Pediatr,2008,1(1):48-56.
[26]Klimo P,Thompson CJ,Ragel BT,et al.Antibiotic-impregnated shunt systems versus standard shunt systems:a meta- and cost-savings analysis[J].J Neurosurg Pediatr,2011,8(6):600-612.
[27]Lane JD,Mugamba J,Ssenyonga P,et al.Effectiveness of the bactiseal Universal shunt for reducing shunt infection in a sub-Saharan African context:a retrospective cohort study in 160 ugandan children[J].J Neurosurg Pediatr,2014,13(2):140-144.
[28]Jenkinson MD,Gamble C,Hartley JC,et al.The British antibiotic and silver-impregnated catheters
for ventriculoperitoneal shunts multi-centre randomised controlled trial (the BASICS trial):study protocol[J].Trials,2014,15(1):4.
[29]Rekate HL.Shunt-related headaches:the slit ventricle syndromes[J].Childs Nerv Syst,2008,24(4):423-430.
[30]Kulkarni AV,Drake JM,Kestle JR,et al.Endoscopic third ventriculostomy vs cerebrospinal fluid shunt in the treatment of hydrocephalus in children:a propensity score-adjusted analysis[J].Neurosurg,2010,67(3):588-593.
[31]Durnford AJ,Kirkham FJ,Mathad N,et al.Endoscopic third ventriculostomy in the treatment of childhood hydrocephalus:validation of a success score that predicts long-term outcome[J].J Neurosurg Pediatr,2011,8(5):489-493.
[32]Kulkarni AV,Drake JM,Kestle JR,et al.Predicting who will benefit from endoscopic third ventriculostomy compared with shunt insertion in childhood hydrocephalus using the ETV Success Score[J].Neurosurg Pediatr,2010,6(2):310-315.
[33]Sacko O,Boetto S,Lauwers-Cances V,et al.Endoscopic third ventriculostomy:outcome analysis in 368 procedures[J].J Neurosurg Pediatr,2010,5(1):68-74.
[34]Drake JM,Canadian Pediatric Neurosurgery Study G.Endoscopic third ventriculostomy in pediatric patients:the Canadian experience[J].Neurosurg,2007,60(5):881-886.
[36]Cinalli G,Spennato P,Ruggiero C,et al.Complications following endoscopic intracranial procedures in children[J].Childs Nerv Syst,2007,23(6):633-644.
[37]Bouras T,Sgouros S.Complications of endoscopic third ventriculostomy[J].J Neurosury Pediatr,2011,7(6):643-649.
重慶市自然科學(xué)基金重點(diǎn)項(xiàng)目(cstc2015jcyjB0226);重慶市衛(wèi)計(jì)委課題(2009-2-264)。作者簡(jiǎn)介:汪迪飛(1993-),碩士,主要從事神經(jīng)外科工作。△
,E-mail:zhaixuan@163.com。
·綜述·10.3969/j.issn.1671-8348.2016.22.046
R726.5
A
1671-8348(2016)22-3145-03
2016-02-14
2016-05-29)